Resources TABS
Explore Our Clinical Research Programs and Publications
Learn about ongoing and completed clinical studies and scientific publications related to investigational therapies for CNS disorders, including DEEs, epilepsies, and essential tremor.
Resilience Program
for children diagnosed with early-onset SCN2A or SCN8A DEE
Recruitment Complete
for children and adults diagnosed with any DEE and related syndrome
Recruitment Open
for children with early-onset SCN2A DEE
Recruitment Open
To learn more about our Resilience Program for DEEs,
visit resiliencestudies.com
Energy Program
for focal onset seizures in adults
Recruitment Complete
for focal onset seizures in adults
Recruitment Open
for adults diagnosed with epilepsy
Recruitment Open
To learn more about our Energy Program for adults living with epilepsy,
visit energyepilepsystudies.com/en
E3 Program
for adults living with essential
tremor (ET)
Recruitment Complete
To learn more about our Essential Tremor Program,
visit praxisessentialtremor.com
Our Expanded Access Policy
Scientific Publications
| 2024 EEC Meeting |
|---|
| Pharmacokinetics, Tolerability and Cardiac Safety for PRAX-628, a Precision Medicine Therapeutic Set to Initiate Registration Enabling Studies for Focal Onset Seizures |
| 2023 AAN Annual Meeting |
|---|
| PRAX-628: A Novel Sodium Channel Blocker with Greater Potency and Activity Dependence Compared to Standard of Care |
| 2022 AES Annual Meeting and Behind the Seizure Scientific Exhibit |
|---|
| A Novel Approach to Assess the Impact of Disease in Patients with SCN8A-Related Developmental and Epileptic Encephalopathy |
| 2021 AES Annual Meeting |
|---|
| Patient-guided Approaches to Drug Development in SCN8A-related Epilepsy: Insights from a Caregiver Survey of Feeding & Medication Formulation Priorities |
| 2023 Oligonucleotides for CNS Meeting |
|---|
| Leveraging Preclinical Models To Inform Clinical Trial Strategy in SCN2A Developmental and Epileptic Encephalopathy |
| 2022 AES Annual Meeting and Behind the Seizure Scientific Exhibit |
|---|
| Disease Impact and Burden in Patients with SCN2A-Related Developmental and Epileptic Encephalopathy |
| 2022 Drug Discovery for Ion Channels XXII Meeting |
|---|
| Using Dynamic Action Potential Clamp Modeling of NaV1.2 Variants to Support the Prediction of Clinical Phenotype in DEE |
| Elsunersen First-in-Human Case in Nature Medicine |
|---|
| Antisense Oligonucleotide Treatment in a Preterm Infant With Early-Onset SCN2A Developmental and Epileptic Encephalopathy |
| 2024 MDS Congress |
|---|
| Essential3: An Innovative Multi-Study Phase 3 Program to Evaluate the Efficacy and Safety of Ulixacaltamide |
| 2024 AAN Annual Meeting |
|---|
| Assessing Clinically Meaningful Improvement Associated with Ulixacaltamide Treatment in Adults with Essential Tremor on Concomitant Propranolol: Findings from Essential1 |
| 2023 IAPRD Meeting |
|---|
| Essential1: Results from a Phase 2 Trial Evaluating the Tolerability, Safety, and Efficacy of Ulixacaltamide in Adults with Essential Tremor |
| 2022 Annual Meeting |
|---|
| Translational Pharmacology of PRAX-944, a Novel T-type Calcium Channel Blocker for the Treatment of Essential Tremor |
| Ulixacaltamide Translational Findings in Movement Disorders |
|---|
| Translational Pharmacology of PRAX-944, a Novel T-Type Calcium Channel Blocker in Development for the Treatment of Essential Tremor |
| ET Claims Analysis in Advances in Therapy |
|---|
| The Hidden Burden of Disease and Treatment Experiences of Patients with Essential Tremor: A Retrospective Claims Data Analysis |
| TTCC Mechanistic Review in Annals of Clinical and Translational Neurology |
|---|
| T-type Calcium Channels as Therapeutic Targets in Essential Tremor and Parkinson's Disease |
| 2025 IEC Meeting |
|---|
| Establishing the Predictive Validity of Preclinical Seizure Models in Generalized Epilepsies: An Extension of the Praxis Analysis of Concordance Framework |
| 2024 EEC Meeting |
|---|
| A Novel Method to Define an EEG Composite for the Detection of Drug Effects of Next Generation Small Molecules for Epilepsy |
| 2023 SYNGAP1 Conference |
|---|
| Progress Toward the Discovery of an ASO for Therapeutic Upregulation of SYNGAP1 |
| 2021 AES Annual Meeting |
|---|
| PRX-2904 is a Small Molecule Selective Inhibitor of KNa1.1 (KCNT1) that Reverses the ECoG Phenotype of a KCNT1 Gain-of-Function Mouse Model |
| PAC-FOS in Epilepsia |
|---|
| PAC-FOS: A Novel Translational Concordance Framework Identifies Preclinical Seizure Models with Highest Predictive Validity for Clinical Focal Onset Seizures |
| PRX-2904 Chemistry in ACS Medicinal Chemistry Letters |
|---|
| Discovery of the First Orally Available, Selective KNa1.1 Inhibitor: In Vitro and In Vivo Activity of an Oxadiazole Series |